New pancreatic indication for Sutent

Sutent (sunitinib) has been approved for the treatment of pancreatic cancer.

It is now licensed for use in patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors who have evidence of disease progression.

Approval for this indication was based on the results of a randomised, double-blind, phase 3 trial in 171 patients who received either 37.5mg sunitinib once daily or placebo. Analysis showed that the duration of progression-free survival was more than doubled in the sunitinib group (11.4 months versus 5.5 months for placebo, p=0.0001).

Sunitinib inhibits multiple receptor tyrosine kinases involved in tumour growth, angiogenesis, and metastasis, including VEGF and PDGF receptors. It was previously approved only for the treatment of advanced/metastatic renal cell carcinoma and unresectable and/or metastatic malignant gastrointestinal stromal tumor.

View Sutent drug record

Further information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more